FDA approved drugs:
(show top 50)
(show all 71)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Actiq
18
|
FENTANYL (citrate) |
Anesta Corporation |
November 1998 |
Disease/s that Drug Treats:cancer pain
Indications and Usage:
18
ACTIQ is an opioid agonist indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. (1) Limitations of Use: ACTIQ may be dispensed only to patients enrolled in the TIRF REMS Access program. (1)
DrugBank Targets:
16
1. Mu-type opioid receptor ;2. Delta-type opioid receptor;3. Kappa-type opioid receptor
Mechanism of Action:
18
Target: -
Action: agonist
FDA: Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.
|
| 2 |
|
Adcetris
18
49
|
BRENTUXIMAB VEDOTIN |
Seattle Genetics |
August 2011 |
Disease/s that Drug Treats:Hodgkin lymphoma and anaplastic large cell lymphoma
Indications and Usage:
18
ADCETRIS is a CD30-directed antibody-drug conjugate indicated fortreatment of patients with: Hodgkin lymphoma after failure of autologous stem cell transplant(ASCT) or after failure of at least two prior multi-agent chemotherapyregimens in patients who are not ASCT candidates (1.1). Systemic anaplastic large cell lymphoma after failure of at least oneprior multi-agent chemotherapy regimen (1.2).Accelerated approval was granted for the above indications based onoverall response rate. An improvement in patient-reported outcomes orsurvival has not been established. Continued approval for these indicationsmay be contingent upon verification and description of clinical benefit inconfirmatory trials.
DrugBank Targets:
16
Tumor necrosis factor receptor superfamily member 8
Mechanism of Action:
18
Target: microtubule
Action: disruptor
FDA: Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. Thesmall molecule, MMAE, is a microtubule disrupting agent. MMAE is covalently attached to theantibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is dueto the binding of the ADC to CD30-expressing cells, followed by internalization of theADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE totubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrestand apoptotic death of the cells.
|
| 3 |
|
Aromasin Tablets
18
49
|
EXEMESTANE |
Pharmacia & Upjohn |
October 21. 1999 |
Disease/s that Drug Treats:advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Indications and Usage:
18
AROMASIN is an aromatase inhibitor indicated for: Incidences of cardiac ischemic events (myocardial infarction, angina, adjuvant treatment of postmenopausal women with estrogen-receptor and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%.positive early breast cancer who have received two to three years of Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6,tamoxifen and are switched to AROMASIN for completion of a total of 6.1).five consecutive years of adjuvant hormonal therapy (14.1). Advanced breast cancer: Most common adverse events were mild to treatment of advanced breast cancer in postmenopausal women whose moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%),disease has progressed following tamoxifen therapy (14.2).
DrugBank Targets:
16
Cytochrome P450 19A1
Mechanism of Action:
18
Target: steroidal aromatase
Action: inactivator
FDA: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that convertsandrogens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarilyestradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausalwomen is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens(estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromataseinhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breastcancer.Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrateandrostenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that bindsirreversibly to the active site of the enzyme, causing its inactivation, an effect also known as âsuicide inhibition.âExemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has nodetectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on otherenzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibitingthe aromatase enzyme.
|
| 4 |
|
Beleodaq
18
49
|
BELINOSTAT |
Spectrum Pharmaceuticals |
July 2014 |
Disease/s that Drug Treats:relapsed or refractory peripheral T-cell lymphoma
Indications and Usage:
18
Beleodaq is a histone deacetylase inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit in theconfirmatory trial. (1)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from thelysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation ofacetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells.Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibitedthe enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).
|
| 5 |
|
Farydak
18
49
|
PANOBINOSTAT LACTATE |
Novartis |
February 2015 |
Disease/s that Drug Treats:Multiple myeloma
Indications and Usage:
18
FARYDAK, a histone deacetylase inhibitor, in combination with bortezomiband dexamethasone, is indicated for the treatment of patients with multiplemyeloma who have received at least 2 prior regimens, including bortezomiband an immunomodulatory agent. This indication is approved underaccelerated approval based on progression free survival. Continued approvalfor this indication may be contingent upon verification and description ofclinical benefit in confirmatory trials. (1)
DrugBank Targets:
-
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: FARYDAK is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs atnanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histonesand some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins,an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation. In vitro,Reference ID: 3699607 panobinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/orapoptosis of some transformed cells. Increased levels of acetylated histones were observed in xenografts frommice that were treated with panobinostat. Panobinostat shows more cytotoxicity towards tumor cells comparedto normal cells.
|
| 6 |
|
Faslodex
18
49
|
FULVESTRANT |
AstraZeneca |
April 2002 |
Disease/s that Drug Treats:Hormone receptor positive metastatic breast cancer
Indications and Usage:
18
FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer inpostmenopausal women with disease progression followingantiestrogen therapy.
DrugBank Targets:
16
1. Estrogen receptor
Mechanism of Action:
18
Target: estrogen receptors on tumor cells
Action: antagonist
FDA: Many breast cancers have estrogen receptors (ER) and thegrowth of these tumors can be stimulated by estrogen.Fulvestrant is an estrogen receptor antagonist that binds to theestrogen receptor in a competitive manner with affinitycomparable to that of estradiol and downregulates the ERprotein in human breast cancer cells.In vitro studies demonstrated that fulvestrant is a reversibleinhibitor of the growth of tamoxifen-resistant, as well asestrogen-sensitive human breast cancer (MCF-7) cell lines. Inin vivo tumor studies, fulvestrant delayed the establishment oftumors from xenografts of human breast cancer MCF-7 cellsin nude mice. Fulvestrant inhibited the growth of establishedMCF-7 xenografts and of tamoxifen-resistant breast tumorxenografts.Fulvestrant showed no agonist-type effects in in vivouterotropic assays in immature or ovariectomized mice andrats. In in vivo studies in immature rats and ovariectomizedmonkeys, fulvestrant blocked the uterotrophic action ofestradiol. In postmenopausal women, the absence of changesin plasma concentrations of FSH and LH in response tofulvestrant treatment (250 mg monthly) suggests no peripheralsteroidal effects.
|
| 7 |
|
Gardasil
18
49
|
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine |
Merck |
June 2006 |
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:
18
GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets:
-
Mechanism of Action:
18
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.
|
| 8 |
|
Gleevec
18
49
|
IMATINIB MESYLATE |
Novartis |
May 2001 |
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:
18
Gleevec⢠(imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:
16
1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:
18
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
|
| 9 |
|
Ibrance
18
49
|
PALBOCICLIB |
Pfizer |
February 2015 |
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:
18
IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:
16
1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:
18
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
|
| 10 |
|
Inlyta
18
49
|
AXITINIB |
Pfizer |
January 2012 |
Disease/s that Drug Treats:advanced renal cell carcinoma
Indications and Usage:
18
INLYTA is a kinase inhibitor indicated for the treatment of advancedrenal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:
16
1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3
Mechanism of Action:
18
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growthfactor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. Thesereceptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediatedendothelial cell proliferation and survival were inhibited by axitinib in vitro and in mousemodels. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograftmouse models.
|
| 11 |
|
Intron A
18
49
|
INTERFERON ALFA-2B |
Schering-Plough |
December 1997/ December 1995/ March 1997 |
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:
18
Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:
16
1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:
18
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
|
| 12 |
|
Keytruda
18
49
|
PEMBROLIZUMAB |
Merck |
September 2014 |
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:
18
KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:
16
1. Programmed cell death protein 1
Mechanism of Action:
18
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
|
| 13 |
|
Lynparza
18
49
|
OLAPARIB |
AstraZeneca |
December 2014 |
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:
18
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:
16
1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:
18
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
|
| 14 |
|
Nolvadex
18
49
|
TAMOXIFEN CITRATE |
AstraZeneca |
October 1998 |
Disease/s that Drug Treats:Breast Cancer
Indications and Usage:
18
Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. âHigh riskâ is defined as women at least35 years of age with a 5-year predicted risk of breast cancer ⥠1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk ⥠1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer ⥠1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY).
DrugBank Targets:
16
1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C
Mechanism of Action:
18
Target: estrogen receptors
Action: competitor with estraidiol
FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.
|
| 15 |
|
Opdivo
18
49
|
NIVOLUMAB |
Bristol-Myers Squibb |
March 2015/ December 2014, March 2015 |
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma, metastatic squamous non-small cell lung cancer
Indications and Usage:
18
OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2) , OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:
16
1. Programmed cell death protein 1, Programmed cell death protein 1
Mechanism of Action:
18
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2, blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth. , Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
|
| 16 |
|
Photodynamic Therapy (& Photofrin)
18
|
PORFIMER SODIUM |
Sanofi-aventis |
January, 1996 |
Disease/s that Drug Treats:esophageal cancer
Indications and Usage:
18
PHOTOFRIN is a photodynamic therapy drug indicated for:Esophageal Cancer (1.1) Palliation of patients with completely obstructing esophageal cancer, or ofpatients with partially obstructing esophageal cancer who, in the opinion oftheir physician, cannot be satisfactorily treated with Nd:YAG laser therapyEndobronchial Cancer (1.2) Treatment of microinvasive endobronchial non-small-cell lung cancer(NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients withcompletely or partially obstructing endobronchial NSCLCHigh-Grade Dysplasia in Barrettâs Esophagus (1.3) Ablation of high-grade dysplasia (HGD) in Barrettâs esophagus (BE)patients who do not undergo esophagectomy
DrugBank Targets:
-
Mechanism of Action:
18
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) withPHOTOFRIN is a consequence of the propagation of radical reactions.Radical initiation may occur after porfimer sodium absorbs light to forma porphyrin excited state. Spin transfer from porfimer sodium tomolecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumordeath also occurs through ischemic necrosis secondary to vascularocclusion that appears to be partly mediated by thromboxane A2 release.As opposed to a thermal effect, the laser treatment with porfimersodium induces a photochemical effect. The necrotic reaction andassociated inflammatory responses may evolve over several days.
|
| 17 |
|
Photofrin
18
|
PORFIMER SODIUM |
QLT |
January 1998 |
Disease/s that Drug Treats:Non-small cell lung cancer
Indications and Usage:
18
PHOTOFRIN is a photodynamic therapy drug indicated for:Esophageal Cancer (1.1) Palliation of patients with completely obstructing esophageal cancer, or ofpatients with partially obstructing esophageal cancer who, in the opinion oftheir physician, cannot be satisfactorily treated with Nd:YAG laser therapyEndobronchial Cancer (1.2) Treatment of microinvasive endobronchial non-small-cell lung cancer(NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients withcompletely or partially obstructing endobronchial NSCLCHigh-Grade Dysplasia in Barrettâs Esophagus (1.3) Ablation of high-grade dysplasia (HGD) in Barrettâs esophagus (BE)patients who do not undergo esophagectomy
DrugBank Targets:
16
1. Low-density lipoprotein receptor;2. High affinity immunoglobulin gamma Fc receptor I
Mechanism of Action:
18
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) withPHOTOFRIN is a consequence of the propagation of radical reactions.Radical initiation may occur after porfimer sodium absorbs light to forma porphyrin excited state. Spin transfer from porfimer sodium tomolecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumordeath also occurs through ischemic necrosis secondary to vascularocclusion that appears to be partly mediated by thromboxane A2 release.As opposed to a thermal effect, the laser treatment with porfimersodium induces a photochemical effect. The necrotic reaction andassociated inflammatory responses may evolve over several days.
|
| 18 |
|
Zevalin
18
49
|
IBRITUMOMAB TIUXETAN |
Biogen IDEC |
February 2002 |
Disease/s that Drug Treats:Non-Hodgkin's lymphoma
Indications and Usage:
18
Zevalin is a CD20-directed radiotherapeutic antibody administered as part ofthe Zevalin therapeutic regimen indicated for the treatment of patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin'slymphoma (NHL) (1.1). previously untreated follicular NHL who achieve a partial or completeresponse to first-line chemotherapy (1.2).
DrugBank Targets:
16
1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkinâslymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90induces cellular damage by the formation of free radicals in the target and neighboring cells.Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red andwhite pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as thelarge and small intestines.
|
| 19 |
|
Zometa
18
49
|
ZOLEDRONIC ACID |
Novartis |
August 2001/ February 2002 |
Disease/s that Drug Treats:Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:
18
Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bonemetastases from solid tumors, in conjunction with standard antineoplastictherapy. Prostate cancer should have progressed after treatment with atleast one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not beenestablished for use in hyperparathyroidism or nontumor-relatedhypercalcemia. (1.3)
DrugBank Targets:
16
1. Farnesyl pyrophosphate synthase;2. Geranylgeranyl pyrophosphate synthase;3. Hydroxylapatite
Mechanism of Action:
18
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although theantiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid alsoblocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acidinhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factorsreleased by tumors.
|
| 20 |
|
Zykadia
18
49
|
CERITINIB |
Novartis |
April 2014 |
Disease/s that Drug Treats:ALK+ metastatic non-small cell lung cancer
Indications and Usage:
18
ZYKADIA is a kinase inhibitor indicated for the treatment of patients withanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) who have progressed on or are intolerant to crizotinib. Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1) , ZYKADIA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:
16
1. ALK tyrosine kinase receptor, ALK tyrosine kinase receptor
Mechanism of Action:
18
Target: ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1, anaplastic lymphoma kinase (ALK)
Action: kinase inhibitor, highly-selective inhibitor
FDA: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinicallyrelevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediatedphosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitroand in vivo assays.Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins anddemonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinibexhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstratedresistance to crizotinib, at concentrations within a clinically relevant range. , Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinib exhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstrated resistance to crizotinib, at concentrations within a clinically relevant range.
|
| 21 |
|
Advair
18
|
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE |
GlaxoSmithKline |
August 2000 |
Disease/s that Drug Treats:asthma and chronic obstructive pulmonary disease
Indications and Usage:
18
ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: * Treatment of asthma in patients aged 4 years and older. (1.1) * Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: * Not indicated for the relief of acute bronchospasm. (1.1, 1.2)
DrugBank Targets:
16
16
Beta-2 adrenergic receptor|Glucocorticoid receptor|Progesterone receptor|Cytosolic phospholipase A2|Mineralocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: ADVAIR DISKUS: ADVAIR DISKUS contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Inflammation is also a component in the pathogenesis of COPD. In contrast to asthma, however, the predominant inflammatory cells in COPD include neutrophils, CD8+ T-lymphocytes, and macrophages. The effects of corticosteroids in the treatment of COPD are not well defined and inhaled corticosteroids and fluticasone propionate when used apart from ADVAIR DISKUS are not indicated for the treatment of COPD. Salmeterol Xinafoate: Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2- adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits plateletactivating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.
|
| 22 |
|
Alecensa
18
|
ALECTINIB HYDROCHLORIDE |
Roche |
December 2015 |
Disease/s that Drug Treats:ALK-positive, metastatic non-small cell lung cancer
Indications and Usage:
18
ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:
16
ALK tyrosine kinase receptor
Mechanism of Action:
18
Target: ALK and RET
Action: kinase inhibitor
FDA: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib. In mouse models implanted with tumors carrying ALK fusions, administration of alectinib resulted in antitumor activity and prolonged survival, including in mouse models implanted intracranially with ALK-driven tumor cell lines.
|
| 23 |
|
Allegra
18
|
FEXOFENADINE HYDROCHLORIDE |
Hoechst Marion Roussel |
July 1996 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
Seasonal Allergic Rhinitis ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria ALLEGRA is indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals.
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: Fexofenadine hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Fexofenadine inhibited histamine release from peritoneal mast cells in rats. In laboratory animals, no anticholinergic, alpha1-adrenergic or beta-adrenergic-receptor blocking effects were observed. No sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.
|
| 24 |
|
Allegra-D
18
|
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE |
Hoechst Marion Roussel |
March 1998 |
Disease/s that Drug Treats:nasal congestion due to seasonal allergy
Indications and Usage:
18
DrugBank Targets:
16
16
Histamine H1 receptor|Sodium-dependent noradrenaline transporter|Sodium-dependent dopamine transporter|Alpha-1A adrenergic receptor|Alpha-2A adrenergic receptor|Sodium-dependent serotonin transporter|Beta-2 adrenergic receptor|Beta-1 adrenergic receptor|Nuclear factor of activated T-cells, cytoplasmic 1|Tumor necrosis factor|Nuclear factor kappa-light-chain-enhancer of activated B cells|activator protein 1|Interleukin-2
Mechanism of Action:
18
Target: -
Action: -
FDA: antihistamine|nasal decongestant
|
| 25 |
|
Augmentin
18
|
AMOXICILLIN; CLAVULANATE POTASSIUM |
SmithKline Beecham |
February 1996 |
Disease/s that Drug Treats:sinusitis, bronchitis, pneumonia
Indications and Usage:
18
AUGMENTIN is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for treatment of the following: Lower respiratory tract infections (1.1) Acute bacterial otitis media (1.2) Sinusitis (1.3) Skin and skin structure infections (1.4) Urinary tract infections (1.5)
DrugBank Targets:
16
16
Beta-lactamase|Penicillin-binding protein 1A
Mechanism of Action:
18
Target: -
Action: -
FDA: AUGMENTIN is an antibacterial drug. [see Microbiology 12.4]. Amoxicillin is a semisynthetic antibiotic with in vitro bactericidal activity against Grampositive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in AUGMENTIN protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin/clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
|
| 26 |
|
Azmacort
18
|
TRIAMCINOLONE ACETONIDE |
Rhone Poulenc Rorer |
November 1996 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
Azmacort Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. Azmacort Inhalation Aerosol is also indicated for asthma patients who require systemic corticosteroid administration, where adding Azmacort may reduce or eliminate the need for the systemic corticosteroids. Azmacort Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: The precise mechanism of the action of glucocorticoids in asthma is unknown. However, the inhaled route makes it possible to provide effective local anti-inflammatory activity with reduced systemic corticosteroid effects. Though highly effective for asthma, glucocorticoids do not affect asthma symptoms immediately. While improvement in asthma may occur as soon as one week after initiation of Azmacort Azmacort Azmacort Inhalation Aerosol therapy, maximum improvement may not be achieved for 2 weeks or longer.
|
| 27 |
|
Breathe Right
18
|
|
CNS |
June 1996 |
Disease/s that Drug Treats:breathing difficulties due to deviated nasal septum
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 28 |
|
Cafcit Injection
18
|
CAFFEINE CITRATE |
Roxane Laboratories |
September 1999 |
Disease/s that Drug Treats:short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age
Indications and Usage:
18
DrugBank Targets:
16
Adenosine receptor A1|Adenosine receptor A2a|cAMP-specific 3',5'-cyclic phosphodiesterase 4B|Ryanodine receptor 1|Cyclic nucleotide phosphodiesterase|DNA-dependent protein kinase catalytic subunit|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform|Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform|Inositol 1,4,5-trisphosphate receptor|Serine-protein kinase ATM
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 29 |
|
Cedax
18
|
CEFTIBUTEN DIHYDRATE |
Schering-Plough |
December 1995 |
Disease/s that Drug Treats:chronic bronchitis, infection of the middle ear, pharyngitis/tonsillitis
Indications and Usage:
18
CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamaseproducing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent rheumatic fever are not available.
DrugBank Targets:
16
Peptidoglycan synthase FtsI|Penicillin-binding protein 1A|Penicillin-binding protein 1B|Penicillin-binding protein 2
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 30 |
|
Cefazolin and Dextrose USP
18
|
CEFAZOLIN SODIUM |
B Braun Medical |
July 2000 |
Disease/s that Drug Treats:Various bacterial infections, septicemia, endocarditis, and perioperative prophylaxis
Indications and Usage:
18
Cefazolin for Injection USP and Dextrose Injection USP is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: Respiratory tract infections (1.1); urinary tract infections (1.2); skin and skin structure infections (1.3); biliary tract infections (1.4); bone and joint infections (1.5); genital infections (1.6); septicemia (1.7); endocarditis (1.8) and perioperative prophylaxis (1.9).
DrugBank Targets:
16
Penicillin-binding protein 1A|Penicillin-binding protein 1B|Penicillin-binding protein 1C|Penicillin-binding protein 2
Mechanism of Action:
18
Target: -
Action: -
FDA: Cefazolin is an antibacterial drug [see Microbiology (12.4)]. Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.
|
| 31 |
|
Claritin RediTabs
18
|
LORATADINE |
Schering-Plough |
January 1997 |
Disease/s that Drug Treats:seasonal allergy symptoms
Indications and Usage:
18
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 32 |
|
Claritin-D 24 Hour Extended Release Tablets
18
|
LORATADINE; PSEUDOEPHEDRINE SULFATE |
Schering-Plough |
August 1996 |
Disease/s that Drug Treats:nasal congestion
Indications and Usage:
18
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 33 |
|
Covera-HS
18
|
VERAPAMIL HYDROCHLORIDE |
GD Searle, Alza |
January 1996 |
Disease/s that Drug Treats:hypertension, angina
Indications and Usage:
18
COVERA-HS is indicated for the management of hypertension and angina.
DrugBank Targets:
16
Voltage-dependent L-type calcium channel subunit alpha-1C|Voltage-dependent L-type calcium channel subunit alpha-1D|Voltage-dependent L-type calcium channel subunit alpha-1F|Voltage-dependent L-type calcium channel subunit alpha-1S|Voltage-dependent L-type calcium channel subunit beta-1|Voltage-dependent L-type calcium channel subunit beta-2|Voltage-dependent L-type calcium channel subunit beta-3|Voltage-dependent L-type calcium channel subunit beta-4|Voltage-dependent T-type calcium channel subunit alpha-1I|Voltage-dependent T-type calcium channel subunit alpha-1G|Voltage-dependent N-type calcium channel subunit alpha-1B|Voltage-dependent P/Q-type calcium channel subunit alpha-1A|Potassium voltage-gated channel subfamily H member 2|Sodium channel protein type 5 subunit alpha|ATP-sensitive inward rectifier potassium channel 11|Sodium-dependent serotonin transporter
Mechanism of Action:
18
Target: -
Action: -
FDA: In vitro: Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced. In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus. The L-type calcium channel is an oligomeric structure consisting of five putative subunits designated alpha-1, alpha-2, beta, tau, and epsilon. Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). Although they share a similar mechanism of action, calcium channel blockers represent three heterogeneous categories of drugs with differing vascular-cardiac selectivity ratios. Essential hypertension: Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects. It acts as a vasodilator with selectivity for the arterial portion of the peripheral vasculature. As a result, the systemic vascular resistance is reduced and usually without orthostatic hypotension or reflex tachycardia. Bradycardia (rate less than 50 beats/min) is uncommon (<1% with COVERA-HS as assessed by ECG). During isometric or dynamic exercise, COVERA-HS does not alter systolic cardiac function in patients with normal ventricular function. COVERA-HS does not alter total serum calcium levels. However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil. COVERA-HS regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles. Effects in hypertension: COVERA-HS was evaluated in two placebo-controlled, parallel design, double-blind studies of 382 patients with mild to moderate hypertension. In a clinical trial, 287 patients were randomized to placebo, 120 mg, 180 mg, 360 mg, or 540 mg and treated for 8 weeks (the two higher doses were titrated from low doses and maintained for 6 and 4 weeks, respectively). COVERA-HS or placebo was given once daily at 10 pm and blood pressure changes were measured with 36-hour ambulatory blood pressure monitoring (ABPM). The results of these studies demonstrate that COVERA-HS, at 180-540 mg, is a consistently and significantly more effective antihypertensive agent than placebo in reducing ambulatory blood pressures. Over this dose range, the placebo-subtracted net decreases in diastolic BP at trough (averaged over 6-10 pm) were dose-related, ranged from 4.5 to 11.2 mm Hg after 4-8 weeks of therapy, and correlated well with sitting cuff blood pressures. These studies demonstrate that clinically and statistically significant blood pressure reductions are achieved with COVERA-HS throughout the 24-hour dosing period. There were no significant treatment differences between patient subgroups of different age (older or younger than 65 years), sex, race (Caucasian and non-Caucasian) and severity of hypertension at baseline (cuff BP below and above 105 mm Hg). Angina: Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm and is responsible for the effectiveness of verapamil in vasospastic (Prinzmetalâs or variant) as well as unstable angina at rest. Whether this effect plays any role in classical effort angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina. Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles. Effect in chronic stable angina: COVERA-HS was evaluated in two placebocontrolled, parallel design, double-blind studies of 453 patients with chronic stable angina. In the first clinical trial, 277 patients were randomized to placebo, 180 mg, 360 mg, or 540 mg and treated for 4 weeks (the two higher doses were titrated from low doses and maintained for 3 and 2 weeks, respectively). A single dose of 240 mg was compared toplacebo in a separate study of 176 patients. In these studies, COVERA-HS was significantly more effective than placebo in improvement of exercise tolerance. Placeboadjusted net increases in median exercise times at the end of the dosing interval were 0.1 to 1.0 minute for symptom limited duration, 0.3 to 1.4 minutes for time to angina, and 0.1 to 1.1 minutes for time to ST change. Increases in exercise tolerance were in general greater at higher doses, but dose-response relationship was not well defined due to shorter treatment duration for high doses. In addition, in the first study, 24% to 34% of patients treated with COVERA-HS did not experience exercise-limiting angina on exercise treadmill testing (ETT) versus 12% of patients on placebo. Electrophysiologic effects: Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the Ltype (slow) channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner. Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block. Atrioventricular block can occur in patients without preexisting conduction defects (see WARNINGS). COVERA-HS does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization, and conduction in depressed atrial fibers. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil (see WARNINGS). Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.
|
| 34 |
|
Daliresp
18
|
ROFLUMILAST |
Forest Pharmaceuticals |
February 2011 |
Disease/s that Drug Treats:chronic obstructive pulmonary disease
Indications and Usage:
18
DALIRESP is a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. (1, 14) Limitations of Use: DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. (1, 14)
DrugBank Targets:
16
cAMP-specific 3',5'-cyclic phosphodiesterase 4D|cAMP-specific 3',5'-cyclic phosphodiesterase 4A|cAMP-specific 3',5'-cyclic phosphodiesterase 4B|cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Mechanism of Action:
18
Target: phosphodiesterase 4 (PDE4)
Action: selective inhibitor
FDA: Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3',5'-adenosine monophosphate (cyclic AMP)-metabolizing enzyme in lung tissue) activity leads to accumulation of intracellular cyclic AMP. While the specific mechanism(s) by which DALIRESP exerts its therapeutic action in COPD patients is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells.
|
| 35 |
|
Dulera
18
|
FORMOTEROL FUMARATE; MOMETASONE FUROATE |
Merck |
June 2010 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
DULERA combines an inhaled corticosteroid medicine, mometasone furoate (the same medicine found in ASMANEX TWISTHALER), and a long-acting beta2-agonist medicine (LABA), formoterol (the same medicine found in FORADIL® AEROLIZER®). * Inhaled corticosteroids help to decrease inflammation in the lungs. Inflammation in the lungs can lead to asthma symptoms. * LABA medicines are used in people with asthma. LABA medicines help the muscles around the airways in your lungs stay relaxed to prevent asthma symptoms, such as wheezing and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe. In severe cases, wheezing can stop your breathing and may lead to death if not treated right away. DULERA is used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older. DULERA should not be used as a rescue inhaler. Do not use DULERA unless your healthcare provider has taught you and you understand everything. Ask your healthcare provider or pharmacist if you have any questions. * Use DULERA exactly as prescribed. Do not use DULERA more often than prescribed. DULERA comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between DULERA and your other inhaled medications, including the differences in prescribed use and physical appearance. * DULERA should be taken every day as 2 puffs in the morning and 2 puffs in the evening. * If you miss a dose of DULERA, skip your missed dose and take your next dose at your regular time. Do not take DULERA more often or use more puffs than you have been prescribed. * While you are using DULERA 2 times each day, do not use other medicines that contain a longacting beta2-agonist (LABA) for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines. * If you take more DULERA than your healthcare provider has prescribed, get medical help right away if you have any unusual symptoms, such as problems breathing, palpitations, chest pain, increased heart rate, nervousness or shakiness. * Do not change or stop using DULERA or other asthma medicines used to control or treat your breathing problems unless told to do so by your healthcare provider. Your healthcare provider will change your medicines as needed. * DULERA does not relieve sudden asthma symptoms. Always have a rescue inhaler with you to treat sudden symptoms. Use your rescue inhaler if you have breathing problems between doses of DULERA. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you. * Remove the cap from the mouthpiece of the actuator before using DULERA. * DO NOT remove the canister from the actuator because: o You may not receive the correct amount of medication. o The dose counter may not function properly. o Reinsertion may cause the dose counter to count down by 1 and may discharge a puff. * Rinse your mouth with water after each dose (2 puffs) of DULERA. This will help to lessen the chance of getting a yeast infection (thrush) in the mouth and throat. * Do not spray DULERA in your eyes. If you accidentally get DULERA in your eyes, rinse your eyes with water and if redness or irritation continues, call your healthcare provider. * Call your healthcare provider or get medical care right away if: o your breathing problems worsen with DULERA o you need to use your rescue inhaler more often than usual o your rescue inhaler does not work as well for you at relieving symptoms o you need to use 4 or more inhalations of your rescue inhaler for 2 or more days in a row o you use 1 whole canister of your rescue inhaler in 8 weeksâ time o your peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you. o you have asthma and your symptoms do not improve after using DULERA regularly for 1 to 2 weeks
DrugBank Targets:
16
16
Beta-2 adrenergic receptor|Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 36 |
|
DuoNeb
18
|
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE |
Dey Laboratories |
March 2001 |
Disease/s that Drug Treats:Bronchospasm associated with COPD for patients who require more than one bronchodilator
Indications and Usage:
18
DuoNeb® - (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg*) - Inhalation Solution - *Equivalent to 2.5 mg albuterol base - DESCRIPTION - The active components in DuoNeb® Inhalation Solution are albuterol sulfate and ipratropium bromide. Albuterol sulfate, is a salt of racemic albuterol and a relatively selective β2-adrenergic bronchodilator chemically described as α1-[(tert-butylamino)methyl]-4-hydroxy-mxylene-α, α'-diol sulfate (2:1) (salt). It has a molecular weight of 576.7 and the empirical formula is (C13H21NO3)2*H2SO4. It is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol base is salbutamol.Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8- azoniabicyclo [3.2.1]-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1- methylethyl)-, bromide, monohydrate (endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine. It has a molecular weight of 430.4 and the empirical formula is C20H30BrNO3*H2O. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons.
DrugBank Targets:
16
16
Muscarinic acetylcholine receptor M1|Muscarinic acetylcholine receptor M2|Muscarinic acetylcholine receptor M3|Beta-2 adrenergic receptor|Beta-1 adrenergic receptor
Mechanism of Action:
18
Target: beta2-adrenergic|acetylcholine
Action: bronchodilator|blocker of physiologic action
FDA: -
|
| 37 |
|
Esbriet
18
|
PIRFENIDONE |
InterMune |
October 2014 |
Disease/s that Drug Treats:idiopathic pulmonary fibrosis
Indications and Usage:
18
ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF). (1)
DrugBank Targets:
16
Furin
Mechanism of Action:
18
Target: p38 MAP kinase
Action: inhibitor
FDA: The mechanism of action of pirfenidone in the treatment of IPF has not been established.
|
| 38 |
|
Foradil Aerolizer
18
|
FORMOTEROL FUMARATE |
Novartis |
February 2001 (asthma, bronchospasm); September 2001 (COPD) |
Disease/s that Drug Treats:COPD, asthma and bronchospasm
Indications and Usage:
18
FORADIL AEROLIZER is a LABA indicated for: * Treatment of asthma in patients â¥5 years as an add-on to a long-term asthma control medication such as an inhaled corticosteroid. (1.1) * Prevention of exercise-induced bronchospasm (EIB) in patients â¥5 years. (1.2) * Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). (1.3) Important limitations of use: * NOT indicated for the relief of acute bronchospasm. (1.1, 1.3)
DrugBank Targets:
16
Beta-2 adrenergic receptor
Mechanism of Action:
18
Target: beta2-adrenergic receptor|intracellular adenyl cyclase
Action: selective agonist|stimulant
FDA: Formoterol fumarate is a long-acting beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1-receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10%-50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that formoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Formoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
|
| 39 |
|
Grastek
18
|
Timothy Grass Pollen Allergen Extract |
Merck |
April 2014 |
Disease/s that Drug Treats:grass pollen-induced allergic rhinitis
Indications and Usage:
18
GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age. (1)
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: The precise mechanisms of action of allergen immunotherapy are not known.
|
| 40 |
|
Iressa
18
|
GEFITINIB |
AstraZeneca |
May 2003 |
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:
18
IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:
16
Epidermal growth factor receptor
Mechanism of Action:
18
Target: EGFR tyrosine kinase
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.
|
| 41 |
|
Kalydeco
18
|
IVACAFTOR |
Vertex Pharmaceuticals |
January of 2012 |
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:
18
KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patientâs genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:
16
Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:
18
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
|
| 42 |
|
Letairis
18
|
AMBRISENTAN |
Gilead |
June 2007 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): * To improve exercise ability and delay clinical worsening. * In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) (1).
DrugBank Targets:
16
Endothelin-1 receptor|Endothelin B receptor
Mechanism of Action:
18
Target: endothelin receptor
Action: type-A selective antagonist
FDA: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH. Ambrisentan is a high-affinity (Ki=0.011 nM) ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.
|
| 43 |
|
Nucala
18
|
MEPOLIZUMAB |
GlaxoSmithKline |
November 2015 |
Disease/s that Drug Treats:severe asthma
Indications and Usage:
18
NUCALA® is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. [See Clinical Studies (14).] Limitations of Use * NUCALA is not indicated for treatment of other eosinophilic conditions. * NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
DrugBank Targets:
16
Interleukin-5
Mechanism of Action:
18
Target: interleukin-5
Action: antagonist monoclonal antibody (IgG1 kappa)
FDA: Mepolizumab is an interleukin-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma has not been definitively established.
|
| 44 |
|
Orkambi
18
|
IVACAFTOR; LUMACAFTOR |
Vertex Pharmaceuticals |
July 2015 |
Disease/s that Drug Treats:cystic fibrosis
Indications and Usage:
18
ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patientâs genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. (1) Limitations of Use: The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation. (1)
DrugBank Targets:
16
Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:
18
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: oral regulators
FDA: The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. In vitro studies have demonstrated that both lumacaftor and ivacaftor act directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
|
| 45 |
|
Patanase
18
|
OLOPATADINE HYDROCHLORIDE |
Alcon |
April 2008 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
PATANASE Nasal Spray is an H1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. (1)
DrugBank Targets:
16
Histamine H1 receptor|Protein S100-A1|Protein S100-A12|Protein S100-B|Protein S100-A13|Protein S100-A2
Mechanism of Action:
18
Target: H1 -receptor
Action: selective antagonist
FDA: Olopatadine is a histamine H1 -receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
|
| 46 |
|
Portazza
18
|
NECITUMUMAB |
Eli Lilly |
November 2015 |
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:
18
PORTRAZZA⢠is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (1.1) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. (1.2, 5.6, 14.2)
DrugBank Targets:
-
Mechanism of Action:
18
Target: EGFR
Action: blocks the binding of EGFR to its ligands
FDA: Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis. Binding of necitumumab induces EGFR internalization and degradation in vitro. In vitro, binding of necitumumab also led to antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. In in vivo studies using xenograft models of human cancer, including non-small cell lung carcinoma, administration of necitumumab to implanted mice resulted in increased antitumor activity in combination with gemcitabine and cisplatin as compared to mice receiving gemcitabine and cisplatin alone.
|
| 47 |
|
Priftin
18
|
RIFAPENTINE |
Hoechst Marion Roussel |
June 1998 |
Disease/s that Drug Treats:pulmonary tuberculosis
Indications and Usage:
18
DrugBank Targets:
16
DNA-directed RNA polymerase subunit beta'
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 48 |
|
Pulmozyme
18
|
DORNASE ALFA |
Genentech |
December 1996|March 1998 |
Disease/s that Drug Treats:cystic fibrosis
Indications and Usage:
18
PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. (1)
Mechanism of Action:
18
Target: -
Action: -
FDA: PULMOZYME is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.
|
| 49 |
|
Qvar
18
|
BECLOMETHASONE DIPROPIONATE |
Ivax |
May 2002 |
Disease/s that Drug Treats:Asthma
Indications and Usage:
18
QVAR is a corticosteroid indicated for: * Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. (1.1) * Treatment of asthma in patients who require oral corticosteroid therapy. QVAR may reduce or eliminate the need for the systemic corticosteroids. (1.1) Important Limitations: * Not indicated for the relief of acute bronchospasm. (1.1)
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: inflammatory cells
Action: inhibitor/anti-inflammatory
FDA: Beclomethasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Beclomethasone dipropionate is a prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP). Beclomethasone 17 monopropionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 13 times that of dexamethasone, 6 times that of triamcinolone acetonide, 1.5 times that of budesonide and 25 times that of beclomethasone dipropionate. The clinical significance of these findings is unknown. Studies in patients with asthma have shown a favorable ratio between topical anti-inflammatory activity and systemic corticosteroid effects with recommended doses of QVAR.
|
| 50 |
|
Ragwitek
18
|
|
Merck |
April 2014 |
Disease/s that Drug Treats:short ragweed pollen-induced allergic rhinitis
Indications and Usage:
18
RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in adults 18 through 65 years of age. (1)
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: The precise mechanisms of action of allergen immunotherapy are not known.
|
Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 515)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687
|
|
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
apo Pravastatin
apo-Pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
BIDD:GT0773
BRD-K60511616-236-01-4
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
FT-0082682
Juste brand OF pravastatin sodium
KS-5015
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
LS-94713
Mevalothin
Mevalotin
Mevastatin
|
Mevinolin
nchembio.301-comp7
nchembio790-comp15
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
pravastatin
Pravastatin (INN)
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin Sodium
Pravastatin sodium salt
Pravastatin Sodium Salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin tert-Octylamine Salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS 431
RMS-431
sankyo Brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
SQ-31,000
Squibb brand OF pravastatin sodium
UNII-KXO2KT9N0G
Vasten
|
|
| 2 |
|
Levobupivacaine |
Approved, Investigational |
Phase 4 |
|
27262-47-1 |
92253
|
|
Synonyms:
(-)-bupivacaine
(-)-Bupivacaine
(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(S)-1-Butyl-2',6'-pipecoloxylidide
(S)-bupivacaine
(S)-Bupivacaine
27262-47-1
27262-48-2
AC1L3NQM
BIDD:GT0471
C07887
C18H28N2O
CAS-18010-40-7
CHEBI:6149
Chirocaine
CID92253
D08116
|
DB01002
L-(-)-1-Butyl-2',6'-pipecoloxylidide
L-(-)-bupivacaine
L(-)-Bupivacaine
L-(-)-Bupivacaine
Levobupivacaine
Levobupivacaine (INN)
Levobupivacaine [INN:BAN]
Levobupivacaine hydrochloride
LS-109843
LS-187025
LS-187789
MolPort-004-959-713
NCGC00016733-01
NCGC00159482-02
Novabupi
Novabupi (TN)
|
|
| 3 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4,Not Applicable |
|
137-58-6 |
3676
|
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
|
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
| 4 |
|
Epinephrine |
Approved, Vet_approved |
Phase 4,Phase 2,Not Applicable |
|
51-43-4 |
5816
|
|
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenalin
(−)-adrenaline
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(−)-adrenaline
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51028-73-0
51-43-4
51-43-4 (FREE BASE)
A0173
AC-13188
AC1L1L7B
Acetate, epinephrine
Adnephrine
ADR ADRENALINE
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalina
Adrenalina [DCIT]
adrenaline
Adrenaline
Adrénaline
Adrenaline (JP15)
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline/Epinephrine
Adrenalin-Medihaler
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
ADROP
AI3-19015
Allergan brand OF adrenaline hydrochloride
Ana-Guard
Ana-kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthmahaler Mist
Asthmanefrin
Asthma-nefrin
Astmahalin
Astminhal
Balmadren
Bernarenin
BIDD:GT0119
Biorenine
bmse000316
Bosmin
Brevirenin
Bronkaid
Bronkaid mist
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
Chelafrin
CHEMBL679
CID5816
Citanest Forte
Corisol
D00095
d-Adrenaline
DB00668
D-Epifrin
D-Epinephrine
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine acetate
Epinephrine bitartrate
Epinephrine hydrochloride
Epinephrine hydrogen tartrate
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
EPIPEN E Z PEN
Epipen EZ Pen
Epipen JR
EPIPEN JR
Epipen Jr.
|
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
HSCI1_000215
HSDB 4289
Hypernephrin
Hyporenin
Intranefrin
Iontocaine
IOP
Isoptoepinal
Kidoline
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
l-Epinephine
L-epinephrine
L-Epinephrine
l-Epinephrine (synthetic)
l-Epirenamine
L-Epirenamine
Levoadrenaline
Levoepinephrine
Levo-Methylaminoethanolcatechol
Levorenen
Levorenin
Levorenine
Levoreninum
l-Methylaminoethanolcatechol
L-Methylaminoethanolcatechol
Lopac-E-4642
LS-156
Lyodrin
Lyophrin
Medihaler-epi
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
nchembio747-comp9
Nephridine
Nieraline
NSC 62786
NSC62786
Paranephrin
PDSP1_001120
PDSP2_001104
Primatene
Primatene mist
Primatene Mist
R-(-)-Epinephrine
Racemic Epinephrine
Racepinephrine
R-Adrenaline
RCRA waste no. P042
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
Scurenaline
Septocaine
Simplene
Sindrenina
SMP1_000227
Soladren
Sphygmogenin
ST069368
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Susphrine
Sus-phrine
Sus-Phrine
SUS-PHRINE SULFITE-FREE
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
|
|
| 5 |
|
Racepinephrine |
Approved |
Phase 4,Phase 2,Not Applicable |
|
329-65-7 |
838
|
|
Synonyms:
(+-)-Adrenaline
(+-)-Epinephrine
2-(methylamino)-1-(3,4-Dihydroxyphenyl)ethanol
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
Bird brand OF racepinefrine hydrochloride
DL-Adrenaline
Epinephrine hydrochloride, racemic mixture
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Hydrochloride, racepinephrine
Micronefrin
|
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Vaponefrin
|
|
| 6 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 4,Phase 3,Not Applicable |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 7 |
|
Aspirin |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2 |
|
50-78-2 |
2244
|
|
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoate
2-(ACETYLOXY)benzoIC ACID
2349-94-2
26914-13-6
2-Acetoxybenzenecarboxylate
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. empirin
A.S.A. Empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
acide 2-(acétyloxy)benzoïque
Acide acetylsalicylique
acide acétylsalicylique
acido Acetilsalicilico
Acido acetilsalicilico
ácido acetilsalicílico
Acido O-acetil-benzoico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
AI3-02956
AIN
AKOS000118884
Aloxiprimum
ASA
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspirdrops
aspirin
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina
Aspirina 03
Aspirine
Aspir-Mox
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bialpirina
Bialpirinia
BIDD:GT0118
Bi-prin
BRN 0779271
Bufferin
C01405
Caprin
Cardioaspirin
Cardioaspirina
CCRIS 3243
Cemirit
CHEBI:15365
CHEMBL25
CID2244
Claradin
Clariprin
cMAP_000006
Colfarit
component of Midol
component of Synirin
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
Easprin
Easprin (TN)
ECM
Ecolen
Ecotrin
EINECS 200-064-1
Empirin
|
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EU-0100038
Extren
Globentyl
Globoid
Helicon
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
I14-7505
IDI1_000555
Idragin
Istopirin
Kapsazal
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
Levius
Lopac0_000038
Lopac-A-5376
LS-143
Magnecyl
Measurin
Medisyl
Micristin
MLS001055329
MLS001066332
MLS001336045
MLS001336046
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
nchem.859-comp6
NCI60_002222
Neuronika
NINDS_000555
Novid
NSC 27223
NSC27223
NSC406186
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-accetylsalicylic acid
O-Acetoxybenzoate
o-acetoxybenzoic acid
o-Acetoxybenzoic acid
O-Acetoxybenzoic acid
O-Acetylsalicylate
O-acetylsalicylic acid
O-Acetylsalicylic acid
o-carboxyphenyl acetate
o-Carboxyphenyl acetate
O-Carboxyphenyl acetate
O-Carboxyphenyl acetic acid
Persistin
Pharmacin
Pirseal
PL-2200
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
Salacetin
Salcetogen
Saletin
Salicylate acetate
salicylic acid acetate
Salicylic acid acetate
Salicylic acid acetic acid
Salicylic acid, acetate
Salospir
SMR000059138
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
SP 189
SPBio_001838
Spectrum_001245
SPECTRUM1500130
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
ST075414
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII=R16CO5Y76E
UNII-R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
Xaxa
XAXA
Yasta
Zorprin
ZORprin
|
|
| 8 |
|
Iron |
Approved |
Phase 4,Phase 1 |
|
7439-89-6 |
23925
|
|
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
|
Fe-40
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
| 9 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 10 |
|
Cisplatin |
Approved |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 11 |
|
Fluorouracil |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
51-21-8 |
3385
|
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
| 12 |
|
Docetaxel |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
114977-28-5 |
148124
|
|
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
| 13 |
|
leucovorin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
58-05-9 |
6006
143
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 14 |
|
Irinotecan |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
100286-90-6, 97682-44-5 |
60838
|
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
| 15 |
|
Levoleucovorin |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1 |
|
68538-85-2 |
|
|
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
|
Citrovorum factor
Levofolene
Levofolinic acid
L-Folinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
|
|
| 16 |
|
Oxymetazoline |
Approved, Investigational |
Phase 4 |
|
1491-59-4 |
4636
|
|
Synonyms:
1491-59-4
2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol
3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
AC1L1IM1
AC-6370
Afrin Cherry 12 Hour Nasal Spray
Afrin Extra Moisturizing 12 Hour Nasal Spray
Afrin Original 12 Hour Nasal Spray
Afrin Original 12 Hour Nose Drops
Afrin Original 12 Hour Pump Mist
Afrin Sinus 12 Hour Nasal Spray
Biomol-NT_000161
BPBio1_000295
BPBio1_000419
BRD-K16195444-001-01-7
BRN 0886303
BSPBio_000267
BSPBio_002145
C07363
CAS-151615
CHEBI:142520
CHEMBL762
CID4636
D010109
D08322
DB00935
DivK1c_000567
Dristan Long Lasting Mentholated Nasal Spray
Dristan Long Lasting Nasal Mist
Drixoral Nasal Solution
Duramist Plus Up To 12 Hour Nasal Decongestant Spray
EINECS 216-079-1
FT-0082560
Genasal Nasal Spray Up to 12 Hour Relief
H 990
Hazol
HMS2089G03
HSDB 3143
Hydrochloride, oxymetazoline
IDI1_000567
Iliadin
KBio1_000567
KBio2_001531
KBio2_004099
KBio2_006667
KBio3_001645
KBioGR_000908
KBioSS_001531
L000459
Lopac0_000903
Lopac-O-2378
|
LS-104146
MolPort-002-538-313
Nafrine
Nasal Relief 12 Hour Nasal Spray
Navasin
Navisin
NCGC00015766-01
NCGC00015766-02
NCGC00015766-03
NCGC00015766-10
NCGC00022345-02
NCGC00022345-04
NCGC00022345-05
NCGC00022345-06
nchembio705-11
Neo-Synephrine 12 Hour Spray
Nezeril
NINDS_000567
Nostrilla 12 Hour Nasal Decongestant
Operil (TN)
Oximetazolina
Oximetazolina [INN-Spanish]
Oximetazolinum
Oxylazine
oxymeta zoline
Oxymetazolina
oxymetazoline
Oxymetazoline (INN)
Oxymetazoline [INN:BAN]
Oxymetazoline hydrochloride
oxymetazoline hydrochloride crystalline
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymetazolinum [INN-Latin]
Oxymethazoline
Oxymetozoline
Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI)
Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI,8CI)
Prestwick0_000224
Prestwick1_000224
Prestwick2_000224
Prestwick3_000224
Rhinofrenol
Rhinolitan
Sinerol
SPBio_001095
SPBio_002188
Spectrum_001051
Spectrum2_000998
Spectrum3_000533
Spectrum4_000464
Spectrum5_001114
Tocris-1142
UNII-8VLN5B44ZY
Vicks Sinex 12 Hour Nasal Spray
Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief
Visine L.R
Visine L.R.
|
|
| 17 |
|
Dobutamine |
Approved |
Phase 4 |
|
34368-04-2 |
36811
|
|
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-b-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
34368-04-2
34368-04-2 (Parent)
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
52663-81-7 (hydrochloride)
74753-15-4
74753-15-4 (hydrobromide)
AC1L1WFF
AC1Q7AD1
Boehringer ingelheim brand OF dobutamine hydrochloride
BPBio1_000489
BRD-A78322124-003-03-3
BSPBio_000443
C06967
CHEBI:4670
CHEMBL926
CID36811
D03879
DB00841
DL-dobutamine
DL-Dobutamine
Dobucor
Dobuject
Dobutamin
Dobutamin fresenius
Dobutamin hexal
Dobutamin ratiopharm
Dobutamin solvay
Dobutamina
Dobutamina [INN-Spanish]
Dobutamina inibsa
Dobutamina rovi
dobutamine
Dobutamine
Dobutamine (+)-isomer
Dobutamine (USP/INN)
Dobutamine [Usan:Ban:Inn]
Dobutamine [USAN:BAN:INN]
Dobutamine [Usan]
Dobutamine [USAN]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine hydrochloride
Dobutamine Hydrochloride
Dobutamine lactobionate
|
Dobutamine phosphate (1:1) salt, (-)-isomer
Dobutamine tartrate
Dobutamine tartrate (1:1), (R-(r*,r*))-isomer
Dobutamine tartrate (1:1), (S-(r*,r*))-isomer
Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
dobutamine(usp)
Dobutamine, (-)-isomer
Dobutamine, phosphate (1:1) salt (+)-isomer
Dobutamin-ratiopharm
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
EINECS 277-982-4
Eli lilly brand OF dobutamine hydrochloride
Fresenius brand OF dobutamine hydrochloride
Hexal brand OF dobutamine hydrochloride
HMS2089K05
Hydrobromide, dobutamine
Hydrochloride, dobutamine
Inibsa brand OF dobutamine hydrochloride
Inotrex
Irisfarma brand OF dobutamine hydrochloride
Juste brand OF dobutamine hydrochloride
Kendrick brand OF dobutamine hydrochloride
L001157
Lactobionate, dobutamine
Lilly 81929
Lilly brand OF dobutamine hydrochloride
Lopac0_000365
LS-174467
LY 81929
NCGC00015321-05
NCGC00024629-02
NCGC00024629-03
Oxiken
Pisa brand OF dobutamine hydrochloride
Posiject
Prestwick0_000352
Prestwick1_000352
Prestwick2_000352
Prestwick3_000352
rac-dobutamine
rac-Dobutamine
racemic-Dobutamine
Racemic-dobutamine
Racemic-Dobutamine
Ratiopharm brand OF dobutamine hydrochloride
Rovi brand OF dobutamine hydrochloride
Solvay brand OF dobutamine hydrochloride
SPBio_002364
Tartrate, dobutamine
UNII-0WR771DJXV
UNII-3S12J47372
|
|
| 18 |
|
Phenylephrine |
Approved |
Phase 4 |
|
59-42-7 |
6041
|
|
Synonyms:
(-)-m-Hydroxy-a-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
1416-03-1
3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
59-42-7
61-76-7 (hydrochloride)
AC1L1LO9
AC1Q40UF
Adrianol
Ah-Chew
AI3-02402
Ak-dilate
AK-Dilate
Ak-nefrin
AK-Nefrin
Alcon efrin
Alcon Efrin
Alconefrin nasal drops 12
Alconefrin Nasal Drops 12
Alconefrin nasal drops 25
Alconefrin Nasal Drops 25
Alconefrin nasal drops 50
Alconefrin Nasal Drops 50
Alconefrin nasal spray 25
Alconefrin Nasal Spray 25
Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI)
BIDD:GT0157
Biomydrin
BSPBio_002420
C07441
CCRIS 8464
CHEBI:8093
CHEMBL1215
CID6041
Cyclomydril
D08365
DB00388
Dilatair
Dimetane
Dionephrine
DivK1c_000597
Doktors
Duration
EINECS 200-424-8
EINECS 215-810-1
Fenilefrina
Fenilefrina [INN-Spanish]
HSDB 3383
IDI1_000597
I-phrine
I-Phrine
Isophrim
Isophrin
isopto Frin
Isopto Frin
KBio1_000597
KBio2_001581
KBio2_004149
KBio2_006717
KBio3_001640
KBioGR_001313
KBioSS_001581
l-(3-Hydroxyphenyl)-N-methylethanolamine
L-(3-Hydroxyphenyl)-N-methylethanolamine
l-1-(m-Hydroxyphenyl)-2-methylaminoethanol
l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene
l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol
Lopac0_000920
Lopac-P-6126
L-Phenylephedrine
L-Phenylephrine
LS-43027
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
|
Metasynephrine
Metsatonum
Mezaton
Minims phenylephrine
Minims Phenylephrine
m-Methylaminoethanolphenol
M-Methylaminoethanolphenol
MolPort-001-792-191
m-Oxedrine
M-Oxedrine
m-Sympathol
M-Sympathol
m-Sympatol
M-Sympatol
m-Synephrine
M-Synephrine
Mydfrin
NCGC00015825-01
NCGC00015825-02
NCGC00024257-03
NCGC00024257-05
NCGC00024257-06
neo Synephrine
Neofrin
Neophryn
neo-Synephrine
Neosynephrine
Neo-Synephrine
neo-Synephrine nasal drops
Neo-Synephrine Nasal Drops
neo-Synephrine nasal jelly
Neo-Synephrine Nasal Jelly
neo-Synephrine nasal spray
Neo-Synephrine Nasal Spray
neo-Synephrine pediatric nasal drops
NINDS_000597
Nostril
Nostril spray pump
Nostril Spray Pump
Nostril spray pump mild
Nostril Spray Pump Mild
Ocugestrin
Ocu-phrin sterile eye drops
Ocu-Phrin Sterile Eye Drops
Ocu-phrin sterile ophthalmic solution
P0395
PDSP1_001108
PDSP2_001092
Phenoptic
phenylephrine
Phenylephrine
Phenylephrine (INN)
Phenylephrine [INN:BAN]
Phenylephrine hydrochloride
Phenylephrine Minims
Phenylephrine Minims (TN)
Phenylephrine tannate
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin liquifilm
Prefrin Liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief eye drops for red eyes
Relief Eye Drops for Red Eyes
Rhinall
SPBio_001280
Spectrum_001101
Spectrum2_001280
Spectrum3_000770
Spectrum4_000967
Spectrum5_001411
Spersaphrine
Tannate, phenylephrine
Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol
UNII-1WS297W6MV
Vicks sinex
Vicks Sinex
Visadron
|
|
| 19 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260
|
|
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(-)-Arterenol
(-)-Arterenol free base
(-)-Noradrenaline
(-)-NORADRENALINE
(-)-Norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-amino-1-Hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
Abbott brand OF levophed bitartrate
AC1L96ZT
Adrenor
Aktamin
ALBB-006229
Arterenol
Aventis brand OF norepinephrine hydrochloride
Bitartrate, levophed
Bitartrate, noradrenaline
Bitartrate, norepinephrine
bmse000404
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
Hydrochloride, norepinephrine
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
L-3,4-dihydroxyphenylethanolamine
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-Arterenol
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
Levophed bitartrate
L-noradrenaline
|
L-Noradrenaline
L-Norepinephrine
L-NOREPINEPHRINE
LS-42676
LT03330026
LT4
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
noradrenaline
Noradrenaline
Nor-adrenaline
Noradrenaline (JP15)
Noradrenaline bitartrate
Noradrénaline tartrate renaudin
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
norepinefrina
Norepinefrina
Norepinephrin D-tartrate (1:1)
norepinephrine
Norepinephrine
Norepinephrine (INN)
Norepinephrine [INN:JAN]
Norepinephrine bitartrate
Norepinephrine D-tartrate (1:1)
Norepinephrine hydrochloride
Norepinephrine hydrochloride, (+)-isomer
Norepinephrine hydrochloride, (+,-)-isomer
Norepinephrine l-Tartrate (1:1)
Norepinephrine L-tartrate (1:1)
Norepinephrine L-tartrate (1:1), (+,-)-isomer
Norepinephrine L-tartrate (1:1), monohydrate
Norepinephrine L-tartrate (1:1), monohydrate, (+)-isomer
Norepinephrine L-tartrate (1:2)
Norepinephrine L-tartrate, (+)-isomer
Norepinephrine Noradrenalin
Norepinephrine, (+)-isomer
Norepinephrine, (+,-)-isomer
norepinephrinum
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
Nor-epirenan
PDSP1_001111
PDSP2_001095
Renaudin brand OF norepinephrine bitartrate
Renaudin, noradrénaline tartrate
SGCUT00123
SPBio_001048
Spectrum_001009
SPECTRUM1500436
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
STK503776
Sympathin e
Sympathin E
Tartrate renaudin, noradrénaline
to_000024
UNII-X4W3ENH1CV
|
|
| 20 |
|
Rocuronium |
Approved |
Phase 4 |
|
119302-91-9, 143558-00-3 |
441290
|
|
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
|
DB00728
Esmeron
Esmerone
HMS2090E03
NCGC00167433-01
Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide
Rocuronium
Rocuronium bromide
Zemuron
|
|
| 21 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 4 |
|
113775-47-6 |
68602
5311068
|
|
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexmedetomidin
Dexmedetomidina
DEXMEDETOMIDINE
|
Dexmédétomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidine hydrochloride
Dexmedetomidinum
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
Precedex
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
| 22 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
| 23 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
5755
|
|
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
|
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
| 24 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
6741
|
|
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
| 25 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
|
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
| 26 |
|
Bupropion |
Approved |
Phase 4,Phase 2 |
|
34841-39-9, 34911-55-2 |
444
|
|
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
alpha-(tert-butylamino)-m-chloropropiophenone
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
AMFEBUTAMONE HCl
amfebutamonum
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
bupropion
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion [INN:BAN]
Bupropion Hcl
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion hydrocloride
Bupropion SR
Bupropion, (+-)-isomer
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
|
Esteve brand OF bupropion hydrochloride
glaxo Wellcome brand 1 OF bupropion hydrochloride
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
Lopac0_000166
LS-122817
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
Quomen
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum_001663
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
Zyban (anti-smoking)
Zyntabac
|
|
| 27 |
|
Dopamine |
Approved |
Phase 4,Phase 2 |
|
51-61-6, 62-31-7 |
681
|
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
| 28 |
|
Nicotine |
Approved |
Phase 4,Not Applicable |
|
54-11-5 |
942
89594
|
|
Synonyms:
(−
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-methylpyrrolidino)Pyridine
(−)-nicotine
(-)-Nicotine
(-)-Nicotine solution
(+)-Nicotine
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-methylpyrollidino)pyridine
3-(N-methylpyrollidino)Pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-methylpyrrolidino)Pyridine
3-(N-Methylpyrrolidino)pyridine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
3-N-Methylpyrrolidine
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
a -N-Methylpyrrolidine
AC1L3I79
AC1Q3ZOC
AI3-03424
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
BB_NC-0777
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
BIDD:GT0599
Bitartrate, nicotine
Black Leaf
Black Leaf 40
bmse000105
BRD-K05395900-322-02-1
C00745
Campbell's Nico-Soap
Caswell No. 597
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
Commit
CPD000059074
D03365
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
EINECS 200-193-3
Emo-Nik
ENT 3,424
EPA Pesticide Chemical Code 056702
Flux Maag
fumeto Bac
Fumetobac
|
Habitrol
Habitrol (TN)
HSDB 1107
L(-)-nicotine
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MLS001055457
MLS001335905
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
Niagara P.A. Dust
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nico-Dust
Nico-Fume
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
nicotine
Nicotine
Nicotine (compounds related to)
Nicotine (USP)
Nicotine [BSI:ISO]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine Alkaloid
NICOTINE AND SALTS
Nicotine betadex
Nicotine bitartrate
Nicotine Patch
Nicotine polacrilex
Nicotine Polacrilex
nicotine replacement patch
Nicotine tartrate
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nic-Sal
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
NSC 5065
NSC97238
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tartrate, nicotine
Tendust
Transdermal Nicotine
UN1654
|
|
| 29 |
|
Folic Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
59-30-3 |
6037
|
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
|
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 30 |
|
Camptothecin |
Experimental |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
7689-03-4 |
|
|
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
(s)-camptothecin
|
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
|
|
| 31 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
|
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
| 32 |
|
Liver Extracts |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 33 |
|
Lipid Regulating Agents |
|
Phase 4,Phase 1 |
|
|
|
| 34 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
| 35 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
| 36 |
|
Antimetabolites |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 37 |
|
Hypolipidemic Agents |
|
Phase 4,Phase 1 |
|
|
|
| 38 |
|
Vitamins |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 39 |
|
Omega 3 Fatty Acid |
|
Phase 4,Phase 2 |
|
|
|
| 40 |
|
Epinephryl borate |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
| 41 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 42 |
|
Anesthetics |
|
Phase 4,Phase 3,Phase 1,Not Applicable |
|
|
|
| 43 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 44 |
|
Analgesics |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 45 |
|
Proton Pump Inhibitors |
|
Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable |
|
|
|
| 46 |
|
Micronutrients |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 47 |
|
Ferric Compounds |
|
Phase 4 |
|
|
|
| 48 |
|
Trace Elements |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 49 |
|
Hematinics |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 50 |
|
Cola |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1413)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer |
Unknown status |
NCT00628784
|
Phase 4 |
|
| 2 |
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer |
Unknown status |
NCT01038154
|
Phase 4 |
Pravastatin |
| 3 |
A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma |
Unknown status |
NCT00642239
|
Phase 4 |
placebo;Sodium Glycididazole |
| 4 |
Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery |
Unknown status |
NCT00790140
|
Phase 4 |
|
| 5 |
Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX |
Unknown status |
NCT02609425
|
Phase 4 |
|
| 6 |
Postoperative Pain Management After Minimally Invasive Esophagectomy |
Unknown status |
NCT02042313
|
Phase 4 |
|
| 7 |
Radiofrequency in the Treatment of Barrett's Oesophagus |
Unknown status |
NCT02558504
|
Phase 4 |
|
| 8 |
Iron Replacement in Oesophagogastric Neoplasia |
Unknown status |
NCT01927328
|
Phase 4 |
Iron isomaltoside 1000 |
| 9 |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer |
Unknown status |
NCT00274885
|
Phase 4 |
oxaliplatin |
| 10 |
trūFreeze® Palliative Esophageal Cancer |
Recruiting |
NCT03243734
|
Phase 4 |
|
| 11 |
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer |
Completed |
NCT00911092
|
Phase 4 |
Chemotherapy (Fluorouracil and Cisplatin) |
| 12 |
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma |
Not yet recruiting |
NCT03413436
|
Phase 4 |
Lobaplatin;Cisplatin |
| 13 |
INEC Study: Immuno-modulating Enteral Nutrition in Cancer |
Completed |
NCT00333099
|
Phase 4 |
|
| 14 |
Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection |
Completed |
NCT01416077
|
Phase 4 |
|
| 15 |
The Effect of Nutritional Counseling for Cancer Patients |
Completed |
NCT01962272
|
Phase 4 |
|
| 16 |
Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. |
Completed |
NCT00754468
|
Phase 4 |
|
| 17 |
Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy |
Completed |
NCT02320734
|
Phase 4 |
Rocuronium |
| 18 |
HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery |
Enrolling by invitation |
NCT03642093
|
Phase 4 |
|
| 19 |
The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I |
Not yet recruiting |
NCT02845479
|
Phase 4 |
|
| 20 |
The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery |
Completed |
NCT02439905
|
Phase 4 |
Dexmedetomidine;Placebo control |
| 21 |
Barretts oEsophageal Resection With Steroid Therapy Trial |
Not yet recruiting |
NCT02004782
|
Phase 4 |
Prednisolone;Placebo Oral Tablet |
| 22 |
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking |
Completed |
NCT00666978
|
Phase 4 |
bupropion hydrochloride |
| 23 |
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking |
Completed |
NCT00365508
|
Phase 4 |
nicotine lozenge;nicotine patch |
| 24 |
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. |
Completed |
NCT03384511
|
Phase 4 |
Apatinib |
| 25 |
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer |
Recruiting |
NCT02366819
|
Phase 4 |
Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil |
| 26 |
Low-dose Aspirin Therapy for Esophageal Cancer |
Unknown status |
NCT02326779
|
Phase 3 |
Acetylsalicylic acid |
| 27 |
Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer |
Unknown status |
NCT02355249
|
Phase 3 |
|
| 28 |
Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer |
Unknown status |
NCT02866019
|
Phase 3 |
|
| 29 |
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer |
Unknown status |
NCT00509561
|
Phase 2, Phase 3 |
capecitabine;cisplatin |
| 30 |
a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent |
Unknown status |
NCT01054274
|
Phase 3 |
|
| 31 |
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial |
Unknown status |
NCT02319187
|
Phase 3 |
S1;S-1;irinotecan |
| 32 |
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus |
Unknown status |
NCT00002884
|
Phase 3 |
chemotherapy;cisplatin;fluorouracil |
| 33 |
Comparable Study of Different Radiation Dose in Esophageal Carcinoma |
Unknown status |
NCT01937208
|
Phase 3 |
concurrent chemotherapy with radiation |
| 34 |
Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer |
Unknown status |
NCT00686114
|
Phase 3 |
Paclitaxel;Cisplatin;Tarceva |
| 35 |
Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma |
Unknown status |
NCT01034683
|
Phase 3 |
lobaplatin , 5-FU ,leucovorin |
| 36 |
Combination Chemotherapy in Treating Patients With Esophageal Cancer |
Unknown status |
NCT00041262
|
Phase 3 |
cisplatin;epirubicin hydrochloride;fluorouracil |
| 37 |
Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 |
Unknown status |
NCT01398449
|
Phase 3 |
|
| 38 |
Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches |
Unknown status |
NCT01053182
|
Phase 3 |
|
| 39 |
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus |
Unknown status |
NCT00002883
|
Phase 3 |
cisplatin;fluorouracil |
| 40 |
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia |
Unknown status |
NCT00357682
|
Phase 3 |
Esomeprazole;Esomeprazole;Aspirin |
| 41 |
Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy |
Unknown status |
NCT01242124
|
Phase 2, Phase 3 |
|
| 42 |
Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial |
Unknown status |
NCT00193817
|
Phase 3 |
|
| 43 |
The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy |
Unknown status |
NCT01361750
|
Phase 3 |
|
| 44 |
Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial |
Unknown status |
NCT02780921
|
Phase 3 |
|
| 45 |
Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy |
Unknown status |
NCT01402180
|
Phase 2, Phase 3 |
chemotherapy;chemotherapy |
| 46 |
Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers |
Unknown status |
NCT01911832
|
Phase 3 |
|
| 47 |
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer |
Unknown status |
NCT00450203
|
Phase 2, Phase 3 |
capecitabine;cisplatin;Epirubicin;Lapatinib |
| 48 |
Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer |
Unknown status |
NCT02375997
|
Phase 3 |
|
| 49 |
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction |
Unknown status |
NCT01962246
|
Phase 2, Phase 3 |
Oxaliplatin; Capecitabine |
| 50 |
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma |
Unknown status |
NCT02677597
|
Phase 3 |
Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
|
